HanchorBio (漢康生技) is developing a technology for the creation of next generation personalized biotherapeutics. Based in San Francisco, Taipei, and Shanghai, we are led by a group of pharmaceutical industry veterans with proven track-record of success is biologics discovery and global development with bold vision to rewrite immunotherapies. Committed to reactivating the immune system to fight against diseases, our proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to help revolutionize the treatment of people with cancer and other debilitating diseases. Our FBDB™ platform has successfully delivered proof-of-concept data in several in-vivo animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing methodology in CMC, we develop transformative medicines to address unmet medical needs.